Newsbenzinga
AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst
· Published
Article summary
AbbVie reports Phase 3 INTREPID trial results for lutikizumab in treating moderate to severe cases of hidradenitis suppurativa.
An excerpt from the original article.
Comments —
Loading comments…